CoChat
Sign Up
Cited by 275Diabetic Foot Ulcer Assessment and ManagementWound Healing and TreatmentsSkin Diseases and Diabetes

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Sucrose octasulfate dressing versus control dressing in patients with neuroischaemic diabetic foot ulcers (EXPLORER): an international, multicentre, double-blind, randomised, controlled trial.

Edmonds, Michael, Lázaro-Martínez, José Luis, Alfayate-García, Jesus Manuel, Martini, Jacques, Petit, Jean-Michel, Rayman, Gerry, Lobmann, Ralf, Uccioli, Luigi, Sauvadet, Anne, Bohbot, Serge, Kerihuel, Jean-Charles, Piaggesi, Alberto·2018·The Lancet Diabetes & Endocrinology
DOI 10.1016/s2213-8587(17)30438-2
Open this paper in CoChat — free account

Abstract

Background Diabetic foot ulcers are serious and challenging wounds associated with high risk of infection and lower-limb amputation. Ulcers are deemed neuroischaemic if peripheral neuropathy and peripheral artery disease are both present. No satisfactory treatment for neuroischaemic ulcers currently exists, and no evidence supports one particular dressing. We aimed to assess the effect of a sucrose octasulfate dressing versus a control dressing on wound closure in patients with neuroischaemic diabetic foot ulcers.Methods We did a randomised, double-blind clinical trial (Explorer) in 43 hospitals with specialised diabetic foot clinics in France, Spain, Italy, Germany, and the UK. Eligible participants were inpatients or outpatients aged 18 years or older with diabetes and a non-infected neuroischaemic diabetic foot ulcer greater than 1 cm 2 and of grade IC or IIC (as defined by the University of Texas Diabetic Wound Classification system). We excluded patients with a severe illness that might lead to them discontinuing the trial and those who had surgical revascularisation in the month before study entry. We randomly assigned participants (1:1) via a computer-generated randomisation procedure (concealed block size two); stratified by study centre and wound area (1-5 cm 2 and 5-30 cm 2), to treatment with either a sucrose octasulfate wound dressing or a control dressing (the same dressing without sucrose octasulfate) for 20 weeks. Both groups otherwise received the same standard of care for a 2-week screening period before randomisation and throughout the 20-week trial. Dressings were applied by nursing staff (or by instructed relatives for some outpatients). Frequencies of dressing changes were decided by the investigator on the basis of the clinical condition of the wound. Patients were assessed 2 weeks after randomisation, then monthly until week 20 or occurrence of wound closure. The primary outcome, assessed by intention-to-treat, was proportion of patients with wound closure at week 20. This trial is registered with ClinicalTrials.gov, number NCT01717183.Findings Between March 21, 2013, and March 31, 2016, we randomly assigned 240 individuals to treatment: 126 to the sucrose octasulfate dressing and 114 to the control dressing. After 20 weeks, wound closure occurred in 60 patients (48%) in the sucrose octasulfate dressing group and 34 patients (30%) in the control dressing group (18 percentage points difference, 95% CI 5-30; adjusted odds ratio 2·60, 95% CI 1·43-4·73; p=0·002). In both groups, the most frequent adverse events were infections of the target wound: 33 wound infections in 25 (20%) patients of 126 in the sucrose octasulfate dressing group and 36 in 32 (28%) patients of 114 in the control dressing group. Minor amputations not affecting the wound site were also reported in one (1%) patient in the sucrose octasulfate dressing group and two (2%) patients in the control dressing group. Three (2%) patients assigned to the sucrose octasulfate dressing and four (4%) assigned to the control dressing died, but none of the deaths were related to treatment, procedure, wound progression, or subsequent to amputation.Interpretation A sucrose octasulfate dressing significantly improved wound closure of neuroischaemic diabetic foot ulcers without affecting safety after 20 weeks of treatment along with standard care. These findings support the use of sucrose octasulfate dressing as a local treatment for neuroischaemic diabetic foot ulcers.Funding Laboratoires Urgo Medical.

Overview

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(17)30438-2

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 33 references

Cited by

Sorted by citations

See all 275

Related

Metadata

Authors
Edmonds, M., Lázaro-Martínez, J. L., Alfayate-García, J. M., Martini, J., Petit, J.-M., Rayman, G., Lobmann, R., Uccioli, L., Sauvadet, A., Bohbot, S., Kerihuel, J.-C., & Piaggesi, A.
Affiliations
  • King's College Hospital (GB)
  • Hospital Universitario Fundación Alcorcón (ES)
  • Hôpital Rangueil (FR)
  • CHU Dijon Bourgogne (FR)
  • Ipswich Hospital (GB)
  • Klinikum Stuttgart (DE)
  • University of Rome Tor Vergata (IT)
  • Urgo Laboratories (France) (FR)
  • University of Pisa (IT)
Corresponding author
Edmonds, Michael
ORCID
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2018-03
Volume
6
Issue
3
Pages
186-196
ISSN
2213-8587 (ISSN-L)
DOI
10.1016/s2213-8587(17)30438-2
OpenAlex
W2781465467
Cited by
275
References
33
Citations by year
2026: 27 · 2025: 19 · 2024: 33 · 2023: 41 · 2022: 37 · 2021: 25 · 2020: 42 · 2019: 34 · 2018: 15
FWCI
19.88
Type
journal article
Language
en
Update notices
erratum (2018-04-01)
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet Diabetes & Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
  • Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
  • Research Portal (King's College London) (submittedVersion)
Funders
University of Southern California
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetic Foot Ulcer Assessment and Management
  • Health Sciences › Medicine › Surgery › Wound Healing and Treatments
  • Health Sciences › Medicine › Dermatology › Skin Diseases and Diabetes
Keywords
sucrose octasulfate, wound dressings, diabetic foot ulcer, wound closure, peripheral neuropathy, peripheral arterial disease, wound healing, diabetic foot clinic, wound classification, amputation prevention, wound infection, revascularization, wound debridement
MeSH terms
Aged, Anti-Ulcer Agents, Bandages, Diabetic Neuropathies, Double-Blind Method, Female, Humans, International Agencies, Ischemia, Male, Prognosis, Sucrose, Diabetic Foot

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review